Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study.
BACKGROUND
Recombinant tissue plasminogen activator (rt-PA) is the only FDA approved lytic therapy for acute ischemic stroke. However, there can be complications such as intra-cerebral hemorrhage. This has led to interest in adjuncts such as GP IIb-IIIa inhibitors. However, there is little data on combined therapies. Here, we measure clot lysis for rt-PA and eptifibatide in an in vitro human clot model, and determine the drug concentrations maximizing lysis. A pharmacokinetic model is used to compare drug concentrations expected in clinical trials with those used here. The hypothesis is that there is a range of rt-PA and eptifibatide concentrations that maximize in vitro clot lysis.


METHODS
Whole blood clots were made from blood obtained from 28 volunteers, after appropriate institutional approval. Sample clots were exposed to rt-PA and eptifibatide in human fresh-frozen plasma; rt-PA concentrations were 0, 0.5, 1, and 3.15 μg/ml, and eptifibatide concentrations were 0, 0.63, 1.05, 1.26 and 2.31 μg/ml. All exposures were for 30 minutes at 37 C. Clot width was measured using a microscopic imaging technique and mean fractional clot loss (FCL) at 30 minutes was used to determine lytic efficacy. On average, 28 clots (range: 6-148) from 6 subjects (3-24) were used in each group.


CONCLUSIONS
FCL for control clots was 14% (95% Confidence Interval: 13-15%). FCL was 58% (55-61%) for clots exposed to both drugs at all concentrations, except those at an rt-PA concentration of 3.15 μg/ml, and eptifibatide concentrations of 1.26 μg/ml (Epf) or 2.31 μg/ml. Here, FCL was 43% (36-51) and 35% (32-38) respectively. FCL is maximized at moderate rt-PA and eptifibatide concentration; these values may approximate the average concentrations used in some rt-PA and eptifibatide treatments.
Shaw
George J
GJ
Department of Emergency Medicine, University of Cincinnati, USA. shawge@ucmail.uc.edu
Meunier
Jason M
JM
Lindsell
Christopher J
CJ
Pancioli
Arthur M
AM
Holland
Christy K
CK
D001777:Blood Coagulation / Q000187:drug effects*; D000077542:Eptifibatide; D006801:Humans; D010455:Peptides / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000494:pharmacology*
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator; D000077542:Eptifibatide
Thromb Res. 2006;117(5):603-8
15951005
Ultrasound Med Biol. 2007 Apr;33(4):576-83
17337113
Stroke. 1996 Sep;27(9):1711-8
8784157
Clin Ther. 2004 Mar;26(3):390-8
15110131
Circ Res. 2002 Mar 8;90(4):428-34
11884372
BMC Cardiovasc Disord. 2008 Aug 26;8:19
18727834
Neurosurgery. 2006 Oct;59(4):789-96; discussion 796-7
16915119
Thromb Haemost. 1996 Jan;75(1):127-33
8713791
Thromb Res. 2009;123(3):528-36
18619651
BMC Res Notes. 2009 Jun 30;2:117
19566947
Acoust Res Lett Online. 2005 Jan;6(1):25-29
18080003
CNS Drugs. 2004;18(14):981-8
15584768
Thromb Haemost. 1989 Jun 30;61(3):497-501
2508258
Clin Ther. 2003 Oct;25(10):2564-74
14667957
Am J Cardiol. 2001 Nov 15;88(10):1097-102
11703951
Thromb Res. 1989 Oct 1;56(1):67-75
2512687
N Engl J Med. 2004 Nov 18;351(21):2170-8
15548777
Am J Ophthalmol. 1989 Jul 15;108(1):90-1
2502019
Cerebrovasc Dis. 2005;20(1):18-22
15925878
Circulation. 1997 Feb 18;95(4):846-54
9054741
Circulation. 1996 Sep 1;94(5):1167-74
8790069
Thromb Res. 2009 Jul;124(3):306-10
19217651
BioDrugs. 1999 Feb;11(2):115-23
18031120
Clin Pharmacol Ther. 1989 Aug;46(2):155-62
2503283
J Clin Invest. 1988 Apr;81(4):1284-91
2832448
N Engl J Med. 1995 Dec 14;333(24):1581-7
7477192
Stroke. 2008 Jan;39(1):87-99
18032739
Thromb Haemost. 1995 Mar;73(3):386-91
7667820
Clin Ther. 1998 Mar-Apr;20(2):307-23
9589822
Stroke. 1985 Nov-Dec;16(6):1022-9
4089920
Magn Reson Med. 2000 Dec;44(6):867-72
11108623
J Thromb Thrombolysis. 2001 May;11(3):223-8
11577261
Acad Radiol. 2005 May;12 Suppl 1:S9-13
16106538
Circulation. 2001 Jul 24;104(4):399-405
11468200
Am J Cardiol. 2006 Dec 18;98(12A):10Q-21Q
17169625
Neurol Res. 2005;27 Suppl 1:S29-35
16197821
Chest. 2004 Sep;126(3 Suppl):549S-575S
15383484
Ultrasound Med Biol. 2008 Nov;34(11):1783-92
18468773
Circulation. 2001 Jul 24;104(4):406-11
11468201
Stroke. 2008 Dec;39(12):3268-76
18772447
Surg Neurol. 2006 Feb;65(2):155-61; discussion 161
16427412